Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib

2014 ◽  
Vol 31 (11) ◽  
Author(s):  
Leonardo Gomes da Fonseca ◽  
Romulado Barroso-Sousa ◽  
Afonso da Silva Alves Bento ◽  
Bruna Paccola Blanco ◽  
Gabriel Luis Valente ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Neutrophil To Lymphocyte Ratio ◽  
Advanced Hepatocellular Carcinoma ◽  
Lymphocyte Ratio ◽  
Pre Treatment

Serum neutrophil/lymphocyte ratio as a potential predictor of treatment response for immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e16156-e16156
Author(s):  
Jian He ◽  
Zhiqiang Mo ◽  
Qicong Mai ◽  
Xiaoming Chen
Keyword(s):  
Hepatocellular Carcinoma ◽  
Treatment Response ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Post Treatment ◽  
Advanced Hepatocellular Carcinoma ◽  
Advanced Hcc ◽  
Lymphocyte Ratio ◽  
Pre Treatment

e16156 Background: Neutrophil to lymphocyte ratio (NLR) has been shown to associate with tumor progression. The present study was to investigate the role of NLR on predicting the treatment response for immune checkpoint inhibitors (ICIs) therapy in patients with advanced hepatocellular carcinoma (HCC). Methods: We retrospectively reviewed 81 patients received ICIs for advanced HCC from January 2017 to July 2019. We analyzed whether pre- and first 3 weeks post- treatment serum NLR level was associated with ICIs outcome. Results: In this study, the pre-treatment NLR level ranged from 0.64 to 14.93 among 81 patients. The cut-off level of NLR was set as the median value of 2.79. The objective response rate (ORR) in the patients with NLR＜2.79 (low NLR) was 25.0%, which was significantly better than that of patients with NLR ≥2.79 (high NLR) (7.3%, P ＝0.03). Compared to patients with high NLR, patients with low NLR exhibited significantly longer median progression-free survival (PFS) (3.7 vs 3.0 months, P ＝0.004) and median overall survival (OS) (10.3 vs 7.5 months, P ＝0.001). Multivariate analysis revealed high NLR was an independent unfavourable prognostic factor for PFS (hazard ratio [HR] = 1.857, 95% confidence interval [CI] = 1.093-3.154; P = 0.022) and OS (HR = 2.267, 95% CI = 1.221-4.207; P = 0.009). For the patients with high pre-treatment NLR level, ICIs outcome was stratified more clearly by first 3 weeks post- treatment NLR level. Conclusions: The pre- and first 3 weeks post- treatment serum NLR level could be considered as a predictive factor of treatment response for ICIs in patients with advanced HCC.

scholarly journals Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma

Oncotarget ◽  
2017 ◽  
Vol 8 (9) ◽  
pp. 14408-14415 ◽  
Author(s):  
Nicola Personeni ◽  
Laura Giordano ◽  
Giovanni Abbadessa ◽  
Camillo Porta ◽  
Ivan Borbath ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Prognostic Value ◽  
Neutrophil To Lymphocyte Ratio ◽  
Advanced Hepatocellular Carcinoma ◽  
Second Line ◽  
Lymphocyte Ratio ◽  
Arq 197

Baseline neutrophil-to-lymphocyte ratio (NLR) and early toxicity as prognostic factors in advanced hepatocellular carcinoma patients treated with sorafenib.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e15159-e15159
Author(s):  
Gema Bruixola ◽  
Oscar Mauricio Niño ◽  
Robert Diaz-Beveridge ◽  
Encarnacion Reche ◽  
Carmen Salvador ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Prognostic Factors ◽  
Neutrophil To Lymphocyte Ratio ◽  
Advanced Hepatocellular Carcinoma ◽  
Lymphocyte Ratio ◽  
Early Toxicity

scholarly journals Erratum to: Neutrophil-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma

Tumor Biology ◽  
2016 ◽  
Vol 37 (9) ◽  
pp. 12903-12903
Author(s):  
Xing Li ◽  
Zhan-Hong Chen ◽  
Xiao-Kun Ma ◽  
Jie Chen ◽  
Dong-Hao Wu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Prognostic Factor ◽  
Neutrophil To Lymphocyte Ratio ◽  
Advanced Hepatocellular Carcinoma ◽  
Lymphocyte Ratio

Neutrophil-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma

Tumor Biology ◽  
2014 ◽  
Vol 35 (11) ◽  
pp. 11057-11063 ◽  
Author(s):  
Xing Li ◽  
Zhan-Hong Chen ◽  
Xiao-Kun Ma ◽  
Jie Chen ◽  
Dong-Hao Wu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Prognostic Factor ◽  
Neutrophil To Lymphocyte Ratio ◽  
Advanced Hepatocellular Carcinoma ◽  
Lymphocyte Ratio

scholarly journals Factors Affecting Therapeutic Effects in 17 Patients with Advanced Hepatocellular Carcinoma Who Were Treated with Sorafenib for More than 12 Months

2018 ◽  
Vol 11 (3) ◽  
pp. 711-720 ◽  
Author(s):  
Kazuhiro Katayama ◽  
Ryosuke Kiyota ◽  
Toshihiro Imai ◽  
Yutaro Abe ◽  
Tadatoshi Nawa ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Adverse Events ◽  
Bilirubin Level ◽  
Total Bilirubin ◽  
Total Bilirubin Level ◽  
Neutrophil To Lymphocyte Ratio ◽  
Therapeutic Effects ◽  
Advanced Hepatocellular Carcinoma ◽  
Factors Affecting ◽  
Lymphocyte Ratio

Background and Objective: Sorafenib is recommended for treating advanced hepatocellular carcinoma. However, it is frequently discontinued because of adverse events, which greatly affects its therapeutic effects. Furthermore, because patients treated with sorafenib for a long period can presumably tolerate adverse events, this study aimed to identify their characteristics and analyze factors affecting the therapeutic effects of the drug. Subjects and Methods: Seventeen patients with hepatocellular carcinoma who received sorafenib for 12 months or longer at our hospital between January 2009 and October 2015 were included. In these 17 patients, factors affecting the time to untreatable progression were analyzed using a Cox proportional hazards model, Kaplan-Meier curve, and log-rank test. Results: In the 17 patients, the mean sorafenib dose was 433 mg/day. The drug was discontinued in 12 patients, 9 (75%) of whom discontinued it because of progressive disease. The median time to untreatable progression was 23.1 months. The contributors to favorable therapeutic effects included administration of at least two sessions of concomitant therapy after initiating sorafenib therapy, a low neutrophil-to-lymphocyte ratio, and a decreased total bilirubin level. Conclusion: Achieving favorable therapeutic effects of sorafenib requires strict dose adjustment that allows better control of adverse events and long-term administration of the drug. Furthermore, combining sorafenib with other therapies, a low neutrophil-to-lymphocyte ratio, and a decreased total bilirubin level are useful predictors of favorable effects.

Sign in / Sign up

Export Citation Format

Share Document